CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
ST
Scribe TherapeuticsClinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
5 Pulse stories
Total Raised
$180M
Celea TherapeuticsScribe Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
2018
Boston, MA
HQ
Alameda, California
Private
Status
Public (SCTX)
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Scribe Therapeutics investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Scribe Therapeutics.